7‐year follow‐up after stereotactic ablative radiotherapy for patients with stage I non–small cell lung cancer: Results of a phase 2 clinical trial

B Sun, ED Brooks, RU Komaki, Z Liao, MD Jeter… - Cancer, 2017 - Wiley Online Library
BACKGROUND The authors evaluated the efficacy, patterns of failure, and toxicity of
stereotactic ablative radiotherapy (SABR) for patients with medically inoperable, clinical …

Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer

FJ Lagerwaard, NE Verstegen, CJA Haasbeek… - International Journal of …, 2012 - Elsevier
BACKGROUND: Approximately two-thirds of patients with early-stage non-small-cell lung
cancer (NSCLC) in The Netherlands currently undergo surgical resection. As an increasing …

Stereotactic ablative radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study

U Ricardi, G Frezza, AR Filippi, S Badellino, M Levis… - Lung cancer, 2014 - Elsevier
Objectives Aim of this retrospective multicenter observational study was to provide data on
outcomes and prognostic factors in patients affected with stage I histologically confirmed …

[HTML][HTML] Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer

JY Chang, H Liu, P Balter, R Komaki, Z Liao, J Welsh… - Radiation …, 2012 - Springer
Background Stereotactic ablative radiotherapy (SABR) can achieve excellent local control
rates in early-stage non-small cell lung cancer (NSCLC) and has emerged as a standard …

Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis

S Senthi, FJ Lagerwaard, CJA Haasbeek… - The lancet …, 2012 - thelancet.com
Background Stereotactic ablative radiotherapy (SABR) is increasingly used in the treatment
of medically inoperable early stage non-small-cell lung cancer (NSCLC). Because patterns …

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified …

JY Chang, RJ Mehran, L Feng, V Verma, Z Liao… - The Lancet …, 2021 - thelancet.com
Background A previous pooled analysis of the STARS and ROSEL trials showed higher
survival after stereotactic ablative radiotherapy (SABR) than with surgery for operable early …

[HTML][HTML] Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort

F Soldà, M Lodge, S Ashley, A Whitington… - Radiotherapy and …, 2013 - Elsevier
Background and purpose To assess the efficacy of stereotactic ablative radiotherapy (SABR)
for the treatment of non-small cell lung cancer (NSCLC) through a systematic review of all …

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised …

D Ball, GT Mai, S Vinod, S Babington, J Ruben… - The Lancet …, 2019 - thelancet.com
Background Stereotactic ablative body radiotherapy (SABR) is widely used to treat
inoperable stage 1 non-small-cell lung cancer (NSCLC), despite the absence of prospective …

[HTML][HTML] Use of stereotactic ablative radiotherapy (SABR) in non–small cell lung cancer measuring more than 5 cm

H Tekatli, S van't Hof, EJ Nossent, M Dahele… - Journal of Thoracic …, 2017 - Elsevier
Introduction Stereotactic ablative radiotherapy (SABR) is currently not the guideline-
recommended treatment for lung tumors measuring more than 5 cm. However …

Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: comparing survival outcomes in adenocarcinoma and squamous cell carcinoma

S Abel, S Hasan, R White, L Schumacher, G Finley… - Lung Cancer, 2019 - Elsevier
Purpose Recent retrospective studies have demonstrated mixed results regarding the
histologic association of squamous cell carcinoma (SCC) with reduced overall survival in …